-
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
van der Hoek, S., Koomen, J. V., van Bommel, E. J. M., Mosterd, C. M., Scholtes, R. A., Hesp, A. C., Stevens, J., van Raalte, D. H. & Heerspink, H. J. L., 1 May 2023, In: Journal of Personalized Medicine. 13, 5, 747.Research output: Contribution to journal › Article › Academic › peer-review
-
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
Scholtes, R. A., Mosterd, C. M., Hesp, A. C., Smits, M. M., Heerspink, H. J. L. & van Raalte, D. H., Jan 2023, In: Diabetes, Obesity and Metabolism. 25, 1, p. 198-207 10 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes
Scholtes, R. A., Hesp, A. C., Mosterd, C. M., Geurts, F., Hoorn, E. J., Touw, D. J., Krebber, M. M., Joles, J. A., Heerspink, H. J. L. & van Raalte, D. H., 13 Dec 2022, In: Circulation. 146, 24, p. 1895-1897 3 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications